Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Aspart; Insulin degludec, insulin aspart drug combination; Insulin Glargine; Insulin, Globin Zinc; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Subjects with type 2 diabetes for more than 2 years

• Subjects currently treated with unchanged insulin glargine dose (10 -100 units) for 2 weeks

• Subjects currently treated with unchanged dose(s) for at least 1 month on one or two Oral Anti-diabetic drugs

• BMI 25 - 40 kg/m2

• HbA1c < 9.5 %

Exclusion Criteria:

• Known or suspected allergy to trial product(s) or related products

• Previous randomisation in this trial

• Pregnancy, breast-feeding, intention of becoming pregnant or pre-menopausal women judged not to be using adequate contraceptive measures (Only sterilisation, intra uterine devices and contraceptive pills are considered adequate contraceptive methods)

• Mental incapacity, unwillingness or language barriers precluding adequate understanding and co-operation.

• Any other significant illness such as endocrine, cardiac, neurological, malignant or other pancreatic illness judged by Investigator

• Participation in other studies within the last three months